de Groot E, Jukema J W, van Boven A J, Reiber J H, Zwinderman A H, Lie K I, Ackerstaff R A, Bruschke A V
Interuniversity Cardiology Institute, Utrecht, The Netherlands.
Am J Cardiol. 1995 Sep 28;76(9):40C-46C. doi: 10.1016/s0002-9149(99)80469-x.
Few data are available about the potential benefit of serum cholesterol reduction in the broad range of patients with coronary atherosclerosis and normal to moderately elevated serum cholesterol levels. REGRESS is a double-blind, placebo-controlled, multicenter study to assess the effect of a 2-year treatment with the 3-hydroxy-3-methylglutaryl co-enzyme A reductase inhibitor pravastatin on progression and regression of coronary atherosclerosis using quantitative coronary arteriography in 885 male patients with a total serum cholesterol value of 155-310 mg/dl (4-8 mmol/liter). Among symptomatic men with significant coronary atherosclerosis and normal to moderately raised levels of serum cholesterol, patients treated with pravastatin had less progression of coronary atherosclerosis and fewer new cardiovascular events than patients in the placebo group. Ultrasound examinations of carotid and femoral arteries were performed in 255 patients. Changes in intimal-medial thickness also showed a treatment effect from pravastatin; however, on a per patient basis, there was no correlation with the treatment effect in the coronary arteries.
关于在广泛的冠状动脉粥样硬化且血清胆固醇水平正常至中度升高的患者中降低血清胆固醇的潜在益处，目前可用的数据很少。REGRESS是一项双盲、安慰剂对照、多中心研究，旨在评估使用3-羟基-3-甲基戊二酰辅酶A还原酶抑制剂普伐他汀进行为期2年的治疗对885名血清总胆固醇值为155 - 310 mg/dl（4 - 8 mmol/升）的男性患者冠状动脉粥样硬化进展和消退的影响，采用定量冠状动脉造影术。在有症状且冠状动脉粥样硬化显著、血清胆固醇水平正常至中度升高的男性中，接受普伐他汀治疗的患者与安慰剂组患者相比，冠状动脉粥样硬化进展较少，新的心血管事件也较少。对255名患者进行了颈动脉和股动脉的超声检查。内膜中层厚度的变化也显示了普伐他汀的治疗效果；然而，就每位患者而言，与冠状动脉的治疗效果并无相关性。
